Loading...
*  Humanized Monoclonal Antibody Solutions in Neoplastic Disease
In this informative article, I can give a brief introduction about custom antibody.... ... when some one mentions the word custom antibody, few people know it. ... Humanized Monoclonal Antibody Solutions in Neoplastic Disease. However, when some one mentions the word custom antibody, few ... Each antibody has a unique "paratope" that may tag the precise "epitope" on the antigen. Under this holding system, an antibody ...
https://www.dailystrength.org/journals/humanized-monoclonal-antibody-solutions-in-neoplastic-disease
*  DailyMed - Search Results for Antibodies, Monoclonal, Humanized
SEARCH RESULTS for: Antibodies, Monoclonal, Humanized [Drug Class] (3 results) * Share : JavaScript needed for Sharing tools. ...
https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Antibodies,%20Monoclonal,%20Humanized&searchdb=class
*  PBEF Neutralizing Humanized Monoclonal Antibodies As Novel Therapeutic Approaches | SBIR.gov
PBEF Neutralizing Humanized Monoclonal Antibodies As Novel Therapeutic Approaches. Printer-friendly version ... and propose to generate therapeutic humanized neutralizing anti-PBEF monoclonal antibodies to treat patients with acute lung ... We therefore propose to generate humanized ant-PBEFmonoclonal antibodies (P- BEFizumab) that can be used as both prophylactic ... Once the credibility of these antibodies in treating patients with ALI/VILI is established, we believe that these antibodies ...
https://www.sbir.gov/sbirsearch/detail/370178
*  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44 | PNAS
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Suping Zhang, Christina C ... Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44 ... We found that a humanized mAb specific for CD44 (RG7356) was directly cytotoxic for leukemia B cells, but had little effect on ...
http://www.pnas.org/content/early/2013/03/22/1221841110
*  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. - PubMed - NCBI
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.. Oliphant T1, Engle M, ... Development of a Humanized Monoclonal Antibody with Therapeutic Potential against West Nile Virus ... Development of a Humanized Monoclonal Antibody with Therapeutic Potential against West Nile Virus ... Development of a Humanized Monoclonal Antibody with Therapeutic Potential against West Nile Virus ...
https://www.ncbi.nlm.nih.gov/pubmed/15852016
*  Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 - Full Text View -...
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29. The safety and scientific ... The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans ... Intervention Details: Biological: CaCP29, a humanized monoclonal antibody CaCP29 or placebo single i.v. infusion in ascending ... Pharmacokinetics and Pharmacodynamics of the New Humanized Monoclonal Antibody CaCP29. ...
https://www.clinicaltrials.gov/ct2/show/NCT01319903
*  Federal Register :: Prospective Grant of Exclusive License: Second Generation Monoclonal Antibodies, and...
Prospective Grant of Exclusive License: Second Generation Monoclonal Antibodies, and Humanized Carcinomas. A Notice by the ... "Variants of Humanized Anti-Carcinoma Monoclonal Antibody CC49" to IDEC Pharmaceutical Corporation of San Diego, California. The ... constituents and/or humanized variants thereof, and excluding bispecific monoclonal antibodies, which are directly conjugated ... U.S. Patent 5,512,443 claims various "second generation" monoclonal antibodies, including CC49, which have binding specificity ...
https://www.federalregister.gov/documents/2000/04/24/00-10166/prospective-grant-of-exclusive-license-second-generation-monoclonal-antibodies-and-humanized
*  A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors |...
... a humanized, anti-endosialin monoclonal antibody, to confirm its tolerability, safety, and pharmacokinetics, and identify... ... Ontuxizumab is a humanized, anti-endosialin, IgG1κ monoclonal antibody with a structure comprising two heavy chains and two ... Background We conducted a first-in-Japanese, phase I study of ontuxizumab, a humanized, anti-endosialin monoclonal antibody, to ... A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors. ...
https://link.springer.com/article/10.1007%2Fs10637-018-0713-7
*  A Phase II Study of Apolizumab, a Humanized Monoclonal Antibody, in Patients With Relapsed or Refractory Follicular, Small...
... is capable of inducing antibody-dependent cellular cytotoxicity, complement-mediated lysis, and direct apoptosis of lymphoma ... The humanized monoclonal antibody apolizumab (Remitogen, Hu1D10), directed against a polymorphic determinant of HLA-DR ... The humanized monoclonal antibody apolizumab (Remitogen, Hu1D10), directed against a polymorphic determinant of HLA-DR ... A Phase II Study of Apolizumab, a Humanized Monoclonal Antibody, in Patients With Relapsed or Refractory Follicular, Small ...
http://www.cancernetwork.com/review-article/phase-ii-study-apolizumab-humanized-monoclonal-antibody-patients-relapsed-or-refractory-follicular
*  TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived...
TAK-701, a humanized monoclonal antibody to HGF, in combination with gefitinib inhibited the phosphorylation of MET, EGFR, ... TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived ... TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived ... TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived ...
http://mct.aacrjournals.org/content/early/2010/09/17/1535-7163.MCT-10-0481
*  A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics,...
Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl ... Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu- ... Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus ... A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without ...
http://clincancerres.aacrjournals.org/content/11/13/4810
*  Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. - Semantic Scholar
The elimination phase half-life (3.8 days) was considerably less than other humanized IgG1 mAbs in the monkey, for which there ... endogenous and antibody-ligand binding) controlling FIX mAb-related effects. ... incorporated Factor IX synthesis and degradation rates that were interrupted by the sequestration of Factor IX by the antibody ... of a humanized anti-Factor IX IgG1 monoclonal antibody (SB 249417, FIX mAb) were studied in Cynomolgus monkeys. Single i.v. ...
https://www.semanticscholar.org/paper/Pharmacokinetics-and-pharmacodynamics-of-a-antibody-Benincosa-Chow/d15206f7fc5014fe8e632aa0d76f559ad921b28b
*  Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking...
Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking ...
https://insights.ovid.com/pubmed?PMID=29057618
*  Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 ...
Therefore, humanized monoclonal antibody BIWA 4 (bivatuzumab), with an intermediate affinity for CD44v6, was recently selected ... The development of human anti-human antibody (HAHA) responses was determined. Administration of 99mTc-BIWA 4 was well tolerated ... Previous studies have shown the potential of murine and chimeric anti-CD44v6 monoclonal antibodies (MAbs) for ... Therefore, humanized monoclonal antibody BIWA 4 (bivatuzumab), with an intermediate affinity for CD44v6, was recently selected ...
https://www.semanticscholar.org/paper/Safety%2C-biodistribution%2C-pharmacokinetics%2C-and-of-4-Colnot-Roos/6d8fe3600c7271472e078dd06427ec3821dd1ed6
*  Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a...
... neutralizing humanized monoclonal antibody, hE16, was previously shown to improve the survival of WNV-infected hamsters when it ... A potent anti-West Nile virus (anti-WNV)-neutralizing humanized monoclonal antibody, hE16, was previously shown to improve the ... Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a ... Antibodies, Monoclonal / administration & dosage*, blood, cerebrospinal fluid, therapeutic use*. Antiviral Agents / therapeutic ...
http://www.biomedsearch.com/nih/Defining-limits-treatment-with-humanized/17452485.html
*  Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D | Cancer...
Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D. Alan S. ... Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D ... Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D ... Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D ...
http://cancerres.aacrjournals.org/content/71/8_Supplement/3667
*  Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2...
... humanized 3F8' (Hu3F8) when combined with interleukin-2 (rIL2) is safe for treating neuroblastoma and othe ... Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk ... Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk ... or hu14.18 treatment must have HAHA antibody titer less than or = to 1300 Elisa. units/ml. - White blood cell count ≥1000/ul. ...
http://www.knowcancer.com/cancer-trials/NCT01662804/
*  Patent US8088908 - Humanized anti-prostate stem cell antigen monoclonal antibody - Google Patents
Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the ... These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take ... The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed ... These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection ...
http://www.google.co.uk/patents/US8088908
*  Humanized Monoclonal Antibodies to Hepatocyte Growth Factor - Patent application
A humanized antibody is a genetically engineered (monoclonal) antibody in which the CDRs from a mouse antibody ("donor antibody ... donor antibody is also transferred to the humanized antibody. Thus, a humanized antibody is an antibody having CDRs from a ... antibody reduce or eliminate binding of the other. 2. Humanized Neutralizing Anti-HGF Antibodies [0029]A monoclonal antibody ( ... A humanized monoclonal antibody (mAb) that binds and neutralizes human Hepatocyte Growth Factor (HGF), the humanized antibody ...
http://www.patentsencyclopedia.com/app/20100278815
*  Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced...
Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 A single infusion of 225Ac-HuM195 will be ... Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in ... Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced ... Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 Phase 1 ...
https://clinicaltrials.gov/show/NCT00672165
*  A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With...
A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With ... A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With ... and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with FOLFIRI in patients ...
https://www.centerwatch.com/clinical-trials/listings/73557/metastatic-colorectal-cancer-phase-ib-study-humanized/?radius=50
*  Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal...
Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal ... Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal ... Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal ... Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal ...
http://www.jneurosci.org/content/37/44/10587
*  Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque...
T1h, a novel humanized monoclonal antibody targeting CD6, a co-stimulatory receptor present on T cells, was evaluated as a ... Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque ... Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque ... Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque ...
http://www.jimmunol.org/content/184/1_Supplement/96.13
*  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial...
Although murine components of this humanized monoclonal antibody were almost exclusively limited to the antibody combining ... 1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory ... Phase I/II, open-label multi-dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (MEDI- ... Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial ...
https://pediatrics.aappublications.org/content/102/3/531?ijkey=417e137b19ad60cb2bea621246191b87fb0f8d31&keytype2=tf_ipsecsha
*  Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22...
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9: ... Epratuzumab is a humanized antibody in which the parent antibody has been replaced with ∼90% human IgG1 sequences and the only ... Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. Ola Lindén, Cecilia Hindorf, Eva Cavallin-Ståhl, William A. Wegener, ... Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. Ola Lindén, Cecilia Hindorf, Eva Cavallin-Ståhl, William A. Wegener, ...
http://clincancerres.aacrjournals.org/content/11/14/5215.full